ID   OCI-AML-20
AC   CVCL_UE33
SY   OCI-AML20; Ontario Cancer Institute-Acute Myeloid Leukemia-20
DR   cancercelllines; CVCL_UE33
DR   GEO; GSE120834
DR   Wikidata; Q98128326
RX   PubMed=30352278;
CC   Doubling time: 57 hours (PubMed=30352278).
CC   Karyotypic information: Monosomy of chromosome 7 (PubMed=30352278).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=30352278).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): PubMed=30352278
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 8,11
ST   D16S539: 8,12
ST   D21S11: 30
ST   D5S818: 11,12
ST   D7S820: 8
ST   TH01: 6,9.3
ST   TPOX: 10,11
ST   vWA: 19,20
DI   NCIt; C82426; Acute myeloid leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2) GATA2, MECOM
DI   ORDO; Orphanet_402020; Acute myeloid leukemia with inv3(q21;q26.2) or t(3;3)(q21;q26.2)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   34Y
CA   Cancer cell line
DT   Created: 13-11-18; Last updated: 19-12-24; Version: 10
//
RX   PubMed=30352278; DOI=10.1016/j.exphem.2018.10.006;
RA   Luciani G.M., Xie L.-H., Dilworth D., Tierens A., Moskovitz Y.,
RA   Murison A., Szewczyk M.M., Mitchell A., Lupien M., Shlush L.I.,
RA   Dick J.E., Arrowsmith C.H., Barsyte-Lovejoy D., Minden M.D.;
RT   "Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent
RT   CD34 expression.";
RL   Exp. Hematol. 69:27-36(2019).
//